Price
Financials
Consolidated, Rs crore| Sep 2022 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 79 | 61 | 74 | 83 | 73 | 84 | 106 |
| Expenses | 71 | 51 | 66 | 75 | 65 | 74 | 94 |
| Operating Profit | 9 | 10 | 8 | 8 | 8 | 10 | 11 |
| OPM % | 11% | 17% | 11% | 10% | 11% | 12% | 11% |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Depreciation | 0 | 1 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 8 | 8 | 7 | 6 | 5 | 8 | 10 |
| Tax % | 22% | 24% | 24% | 25% | 41% | 22% | 19% |
| Net Profit | 6 | 6 | 5 | 5 | 3 | 7 | 8 |
| EPS in Rs | 5.40 | 4.46 | 3.66 | 3.17 | 2.40 | 3.59 | 4.20 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 39 | 71 | 99 | 114 | 136 | 156 | 190 |
| Expenses | 36 | 66 | 89 | 98 | 117 | 136 | 168 |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 22 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 12% | 11% |
| Other Income | 1 | 1 | 1 | 1 | 2 | -1 | 2 |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 12 | 18 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% | 20% |
| Net Profit | 1 | 3 | 7 | 10 | 12 | 8 | 14 |
| EPS in Rs | 4.65 | 13.60 | 30.55 | 9.30 | 8.12 | 5.23 | 7.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 22% | 18% | 22% | ||
| Compounded Profit Growth | % | 35% | 9% | 21% | ||
| Stock Price CAGR | % | % | 0% | 7% | ||
| Return on Equity | % | 18% | 14% | 11% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 105 |
| Borrowings | 9 | 11 | 23 | 29 | 11 | 52 | 0 |
| Other Liabilities | 9 | 17 | 23 | 19 | 15 | 37 | 54 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| Fixed Assets | 4 | 5 | 4 | 19 | 20 | 24 | 23 |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Other Assets | 18 | 26 | 46 | 52 | 66 | 144 | 114 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 3 | 7 | 12 | 9 | -13 | -29 | 34 |
| Cash from Investing Activity | -1 | -5 | -7 | -5 | -4 | -27 | -7 |
| Cash from Financing Activity | -1 | -1 | -2 | -3 | 23 | 79 | -32 |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 | -5 |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | 24 |
| CFO/OP | 137% | 168% | 137% | 73% | -51% | -131% | 174% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 | 61 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | 32% | 38% | 36% | 28% | 15% | 13% |
| Sep 2023 | Mar 2024 | Sep 2024 | Nov 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 73.05% | 73.05% | 73.05% | 65.24% | 65.24% | 59.91% | 64.91% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.02% | 0.21% |
| Public | 26.95% | 26.95% | 26.95% | 34.76% | 34.76% | 40.07% | 34.87% |
| No. of Shareholders | 646 | 771 | 947 | 998 | 958 | 1,052 | 1,061 |
Fundamentals
Market Cap₹ 415 Cr.
Current Price₹ 266
Stock P/E34.2
Book Value₹ 77.7
ROCE13.1 %
ROE10.5 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)22%
Compounded Profit Growth (TTM)21%
Consolidated figures.
Valuation
Market capRs 490 Cr
Enterprise valueRs 513 Cr
P/E (TTM)51.60x
Price to book21.71x
Price to sales4.29x
EV / EBITDA29.50x
EV / EBIT31.96x
EV / sales4.49x
Price to cash flow57.01x
Earnings yield1.94%
Profitability
Operating margin (excl. other income)14.04%
Operating margin (incl. other income)15.22%
EBITDA margin15.22%
Pre-tax margin11.34%
Net profit margin8.31%
ROE53.21%
ROCE36.72%
ROA14.64%
ROE, 3-year average54.04%
ROCE, 3-year average35.91%
ROA, 3-year average12.46%
ROIC (approx.)26.54%
Tax rate24.25%
Other income / net worth5.98%
Growth
Sales growth (latest year)15.23%
Profit growth (latest year)55.32%
Sales CAGR, 3 years43.27%
Profit CAGR, 3 years116.90%
Per share
EPS (TTM)Rs 6.09
EPS (latest year)Rs 18.67
EPS, 3-year averageRs 35.18
Book value per shareRs 14.48
Sales per shareRs 73.30
Cash flow per shareRs 5.51
Free cash flow per shareRs 15.40
Efficiency
Asset turnover1.62x
Fixed asset turnover6.07x
Inventory turnover4.17x
Inventory days88 days
Debtor days49 days
Debtors turnover7.40x
Creditor days10 days
Cash conversion cycle146 days
Working capital days99 days
Leverage
Total debtRs 29 Cr
Cash and bankRs 6 Cr
Net debtRs 23 Cr
Debt to equity1.30x
Net debt / EBITDA1.34x
Interest coverage5.18x
Owners' fund to total sources31.95%
Debt to assets41.41%
Cash flow
Cash from Operating Activity (latest year)Rs 9 Cr
Cash from Investing Activity (latest year)Rs -5 Cr
Cash from Financing Activity (latest year)Rs -3 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 24 Cr
FCFE (approx.: FCF + change in debt)Rs 31 Cr
Cash from ops / profit, 5 years0.25x
Sales to cash flow13.30x
Statement figures
Net sales (TTM)Rs 114 Cr
Net sales (latest year)Rs 114 Cr
Operating profit excl. other income (latest year)Rs 16 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 17 Cr
PBDT (TTM)Rs 14 Cr
Profit before tax (TTM)Rs 13 Cr
Tax (latest year)Rs 3 Cr
Net profit (TTM)Rs 9 Cr
Net profit (latest year)Rs 9 Cr
Depreciation (TTM)Rs 1 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 82 Cr
Total expenditure (latest year)Rs 98 Cr
Total income (latest year)Rs 116 Cr
Share capitalRs 5 Cr
ReservesRs 17 Cr
Shareholders' fundsRs 23 Cr
Total assetsRs 71 Cr
Net blockRs 19 Cr
ReceivablesRs 15 Cr
InventoryRs 20 Cr
Other liabilitiesRs 19 Cr
Shares outstanding (crore)1.56
Ownership
Promoter holding64.91% (-8.14 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 51.6 is at the 14th percentile of its own 2.9-year range
(median 112.2, low 33.6, high 395.9).
P/B 21.71 is at the 10th percentile (median 49.91).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | INFINIUM | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +22.5% | -2.8% | +25.2 pts |
| 1 month | +20.1% | -6.8% | +26.9 pts |
| 3 months | +57.1% | -7.6% | +64.7 pts |
| 6 months | +57.0% | +0.4% | +56.6 pts |
| 1 year | +22.6% | -9.9% | +32.6 pts |
| 2 years | +62.7% | -13.6% | +76.2 pts |
| 3 years | +19.0% | +14.2% | +4.8 pts |
Red flags
F-score 4 of 7No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹106 Cr +43.2% vs Mar 2024.
Net profit ₹8 Cr +60.0%.
Against our estimate for Mar 2026: sales +45.3%, profit +71.6% big beat.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 50perc in previous 3 monthsLess than 100 unique PAN traded in previous 30 daysMandatory Market making period in SME scrip is overSME scrip is not regularly traded
Quick answers
What is the market cap of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd (INFINIUM) has a market capitalisation of Rs 415 Cr. at the 2026-10-01 close.
What is the P/E ratio of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd trades at a P/E of 34.2 on trailing twelve-month profit, at the 2026-10-01 close.
What were Infinium Pharmachem Ltd's latest quarterly results?
In the Mar 2026 quarter, Infinium Pharmachem Ltd sales was Rs 106 Cr (+43.2% vs Mar 2024) and net profit was Rs 8 Cr.
What is the 52-week high and low of Infinium Pharmachem Ltd?
The 52-week high is Rs 293.15 and the 52-week low is Rs 189.40.